Abstract
The development of lymphomas and leukemias is frequently caused by chromosomal translocations that deregulate cellular pathways of differentiation, proliferation or survival. The molecules that are involved in these aberrations provide rational targets for selective drug therapies. Recently, several disease specific translocations have been identified in human MALT lymphoma. These aberrations either upregulate the expression of BCL10 or MALT1 or induce the formation of API2-MALT1 fusion proteins. Genetic and biochemical experiments identified BCL10 and MALT1 as central components of an oligomerization - ubiquitinylation – phosphorylation cascade that activates the transcription factor NF-κB in response to antigen receptor ligation. Deregulation of the signaling cascade is directly associated with antigen independent MALT lymphoma growth. Here we provide an overview of the physiological and pathological functions of BCL10 / MALT1 signal transduction and discuss the potential of this pathway as a drug target.
Keywords: Lymphoma, Malt1, Bcl10, API2-MALT1, NF-κB, antigen receptor, chromosomal translocation, fusion protein
Current Drug Targets
Title: The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma
Volume: 7 Issue: 10
Author(s): P. Jost, C. Peschel and J. Ruland
Affiliation:
Keywords: Lymphoma, Malt1, Bcl10, API2-MALT1, NF-κB, antigen receptor, chromosomal translocation, fusion protein
Abstract: The development of lymphomas and leukemias is frequently caused by chromosomal translocations that deregulate cellular pathways of differentiation, proliferation or survival. The molecules that are involved in these aberrations provide rational targets for selective drug therapies. Recently, several disease specific translocations have been identified in human MALT lymphoma. These aberrations either upregulate the expression of BCL10 or MALT1 or induce the formation of API2-MALT1 fusion proteins. Genetic and biochemical experiments identified BCL10 and MALT1 as central components of an oligomerization - ubiquitinylation – phosphorylation cascade that activates the transcription factor NF-κB in response to antigen receptor ligation. Deregulation of the signaling cascade is directly associated with antigen independent MALT lymphoma growth. Here we provide an overview of the physiological and pathological functions of BCL10 / MALT1 signal transduction and discuss the potential of this pathway as a drug target.
Export Options
About this article
Cite this article as:
Jost P., Peschel C. and Ruland J., The Bcl10 / Malt1 Signaling Pathway as a Drug Target in Lymphoma, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559256
DOI https://dx.doi.org/10.2174/138945006778559256 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging Malignant Gliomas with 99mTc-MIBI Brain Single-Photon Emission Computed Tomography
Current Medical Imaging NRF2-Dependent Glutamate-L-Cysteine Ligase Catalytic Subunit Expression Mediates Insulin Protection Against Hyperglycemia-Induced Brain Endothelial Cell Apoptosis
Current Neurovascular Research Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates
Current Medicinal Chemistry Evaluation of Anticancer Activities of Gallic Acid and Tartaric Acid Vectorized on Iron Oxide Nanoparticles
Drug Delivery Letters The Anti-Breast Cancer Effects of Green-Synthesized Zinc Oxide Nanoparticles Using Carob Extracts
Anti-Cancer Agents in Medicinal Chemistry The Role of Hesperidin in Cell Signal Transduction Pathway for the Prevention or Treatment of Cancer
Current Medicinal Chemistry Intracellular and Extracellular miRNAs in Regulation of Angiogenesis Signaling
Current Angiogenesis (Discontinued) Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Clinical Benefit of Idiotype Vaccines: Too Many Trials for a Clever Demonstration?
Reviews on Recent Clinical Trials Targeted Delivery of Natural Bioactives and Lipid-nanocargos against Signaling Pathways Involved in Skin Cancer
Current Medicinal Chemistry Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology Recent Developments in Particulate-Based Vaccines
Recent Patents on Drug Delivery & Formulation Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Notch-Associated MicroRNAs in Cancer
Current Drug Targets Replicative Oncolytic Herpes Simplex Viruses in Combination Cancer Therapies
Current Gene Therapy